Table 4.
Outcome | MICA Matched
|
Single MICA MM
|
Double MICA MM
|
Pointwise
|
|||
---|---|---|---|---|---|---|---|
n | Prob (95% CI) | n | Prob (95% CI) | n | Prob (95% CI) | P Value | |
Survival | 522 | 182 | 9 | 0.21* | |||
1 Yr | 57 (53–61) | 52 (45–59) | 67 (35–92) | .44 | |||
3 Yr | 44 (39–48) | 39 (32–46) | 67 (35–92) | .15 | |||
5 Yr | 38 (34–43) | 33 (26–41) | 67 (35–92) | .09 | |||
DFS | 519 | 182 | 9 | 0.13* | |||
1 Yr | 47 (43–51) | 43 (36–50) | 67 (35–92) | .27 | |||
3 Yr | 38 (34–42) | 33 (26–40) | 67 (35–92) | .08 | |||
5 Yr | 32 (27–36) | 28 (21–35) | 67 (35–92) | .05 | |||
Relapse | 519 | 182 | 9 | ||||
1 Yr | 31 (28–36) | 32 (26–39) | 0 (.–.) | ||||
3 Yr | 35 (31–40) | 36 (30–44) | 0 (.–.) | ||||
5 Yr | 38 (34–43) | 39 (32–46) | 0 (.–.) | ||||
TRM | 519 | 182 | 9 | ||||
1 Yr | 22 (18–25) | 25 (19–31) | 33 (8–65) | .55 | |||
3 Yr | 27 (23–31) | 31 (24–38) | 33 (8–65) | .57 | |||
5 Yr | 30 (26–34) | 34 (27–41) | 33 (8–65) | .70 | |||
Neutrophil engraftment | 521 | 182 | 9 | ||||
28 D | 93 (91–95) | 94 (90–97) | 100 (.–.) | ||||
42 D | 95 (94–97) | 95 (91–98) | 100 (.–.) | ||||
Grades II–IV aGVHD | 520 | 182 | 9 | ||||
100 D | 38 (33–42) | 51 (43–58) | 44 (15–76) | .01 | |||
Grades III and IV aGVHD | 521 | 182 | 9 | ||||
100 D | 16 (13–19) | 18 (13–24) | 33 (8–65) | .49 | |||
cGVHD | 515 | 181 | 8 | ||||
1 Yr | 46 (42–51) | 54 (46–61) | 50 (18–82) | .21 | |||
2 Yr | 52 (48–57) | 58 (51–66) | 75 (42–97) | .15 |
Prob indicates probability (%).
Log-rank P-value.